Catalent | CTLT


Peers Price Chg Day Year Date
Agilent 128.75 0.27 0.21% -6.04% Sep/05
Elevance Health 313.64 5.59 1.81% -42.30% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Bruker 30.83 1.04 3.49% -51.84% Sep/05
Cigna 305.31 1.28 0.42% -13.66% Sep/05
Centene 28.98 0.33 1.15% -59.11% Sep/05
Charles River Laboratories 163.99 1.68 1.04% -12.63% Sep/05
Quest Diagnostics 183.49 3.38 1.88% 20.12% Sep/05
Danaher 200.21 1.18 0.59% -24.77% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
Hologic 66.76 0.37 0.56% -18.16% Sep/05
Humana 307.92 -4.08 -1.31% -13.89% Sep/05
Illumina 98.93 1.25 1.28% -20.47% Sep/05
IQVIA Holdings 187.68 3.60 1.96% -22.83% Sep/05
Intuitive Surgical 466.86 12.34 2.72% -1.06% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Laboratory Of America 278.67 3.44 1.25% 24.30% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Lonza 577.40 -0.80 -0.14% 7.68% Sep/05
McKesson 687.40 -4.05 -0.59% 36.29% Sep/05
Merck 109.55 1.05 0.97% -35.52% Sep/06
Merck 84.71 0.66 0.79% -28.14% Sep/05
Mettler Toledo International 1,305.71 17.92 1.39% -5.26% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Revvity 86.64 0.94 1.10% -24.90% Sep/05
Repligen 124.56 3.98 3.30% -15.31% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Supernus Pharmaceuticals 46.00 0.57 1.25% 35.93% Sep/05
Thermo Fisher Scientific 492.60 3.11 0.64% -19.59% Sep/05
UnitedHealth 315.39 5.01 1.61% -47.18% Sep/05
Waters 306.32 6.63 2.21% -6.72% Sep/05
West Pharmaceutical Services 250.73 3.19 1.29% -15.66% Sep/05
Dentsply International 14.62 0.29 2.02% -42.75% Sep/05

Indexes Price Day Year Date
US400 3297 16.31 0.50% 12.16% Sep/05

Catalent traded at $63.49 this Tuesday December 17th, increasing $0.02 or 0.02 percent since the previous trading session. Looking back, over the last four weeks, Catalent gained 8.03 percent. Over the last 12 months, its price rose by 51.56 percent. Looking ahead, we forecast Catalent to be priced at 62.96 by the end of this quarter and at 61.41 in one year, according to Trading Economics global macro models projections and analysts expectations.

Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.